Skip Navigation LinksGastrointestinal

​​​​​​​Gastrointestinal Trials


Cancer Control/Prevention

S0820: A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrance of High Risk Adenomas and Secondary Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III-Preventing Adenomas of th​e Colon with Eflornithine and Sulindace (PACES) 


Gastric and Gastro-Esophageal


C-13 (ARGO): A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients with Stage III Colon Cancer 


E7208: A Randomized Phase II Study of Irinotecan and Cetuximab with or without the Anti-Angiogenic Antibody, Ramucirumab, in Advanced, K-ras Wild-type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy​

​​MPR-1​: NSABP Patient Registry and Biospecimen Profiling Repository


N1048: A Phase II/III Trial of Neoadujvant FOLFOX with Selective Use of Combined Modality Chemoradiation versus Preoeprative Combined Modality Chemoradiation for Locally Advanced Retal Cancer Patients Undergoing Low Anterior Resection with Mesorectal Excisio​n

GI002: A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer​

​Small Bowel

Pancreas, Adjuvant

S1​​505:  A Randomized Phase II Study of Perioperative mFOLFIRINOX versus Gemcitabine/nab-Paclitaxel as Therapy for Resectable P​ancreatic Adenocarcinoma​

S1513: Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI with PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic cancer

R0848: A Phase IIR and A Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (PhIII) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma​​

Pancreas, Advanced

​​Pancreas, Metastatic 

Liver, Advan​ced​

 Liver, Unresectable

GI001:  Randomized Phase III Study of Focal Radiation Therapy for Unresectable, Localized Intrahepatic Cholangiocarcinoma​ Carcinoid

​EA​2142: Randomized Phase II Study of Platinum and Etoposide versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Carcinomas